Search

Avatrombopag

[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby

Formestane

Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency. … Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.

Diphenoxylate

A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. … This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations.

Solifenacin

[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

Trihexyphenidyl

[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … [L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]

Elapegademase

group in alanine and lysine residues. … [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

Doxercalciferol

Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin

Setmelanotide

[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [L24474] It is an agonist of the melanocortin 4 receptor.

Eliglustat

[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.